HLB Life Science Co. Ltd (067630) - Net Assets
Based on the latest financial reports, HLB Life Science Co. Ltd (067630) has net assets worth ₩277.26 Billion KRW (≈ $187.89 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩450.26 Billion ≈ $305.14 Million USD) and total liabilities (₩173.00 Billion ≈ $117.24 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are HLB Life Science Co. Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩277.26 Billion |
| % of Total Assets | 61.58% |
| Annual Growth Rate | 39.99% |
| 5-Year Change | 38.88% |
| 10-Year Change | 1440.16% |
| Growth Volatility | 86.69 |
HLB Life Science Co. Ltd - Net Assets Trend (2012–2024)
This chart illustrates how HLB Life Science Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 067630 total assets for the complete picture of this company's asset base.
Annual Net Assets for HLB Life Science Co. Ltd (2012–2024)
The table below shows the annual net assets of HLB Life Science Co. Ltd from 2012 to 2024. For live valuation and market cap data, see 067630 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩398.83 Billion ≈ $270.28 Million |
+72.49% |
| 2023-12-31 | ₩231.21 Billion ≈ $156.69 Million |
-1.50% |
| 2022-12-31 | ₩234.72 Billion ≈ $159.07 Million |
-4.66% |
| 2021-12-31 | ₩246.19 Billion ≈ $166.84 Million |
-14.27% |
| 2020-12-31 | ₩287.18 Billion ≈ $194.62 Million |
-13.97% |
| 2019-12-31 | ₩333.82 Billion ≈ $226.23 Million |
+52.37% |
| 2018-12-31 | ₩219.09 Billion ≈ $148.47 Million |
+314.73% |
| 2017-12-31 | ₩52.83 Billion ≈ $35.80 Million |
+90.81% |
| 2016-12-31 | ₩27.68 Billion ≈ $18.76 Million |
+6.91% |
| 2015-12-31 | ₩25.90 Billion ≈ $17.55 Million |
+92.65% |
| 2014-12-31 | ₩13.44 Billion ≈ $9.11 Million |
+21.81% |
| 2013-12-31 | ₩11.03 Billion ≈ $7.48 Million |
+56.71% |
| 2012-12-31 | ₩7.04 Billion ≈ $4.77 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to HLB Life Science Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 36219.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩16.37 Billion | 4.11% |
| Other Components | ₩381.97 Billion | 95.89% |
| Total Equity | ₩398.34 Billion | 100.00% |
HLB Life Science Co. Ltd Competitors by Market Cap
The table below lists competitors of HLB Life Science Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zig Sheng Industrial Co Ltd
TW:1455
|
$136.52 Million |
|
Onde SA
WAR:OND
|
$136.52 Million |
|
Luda Technology Group Limited
NYSE MKT:LUD
|
$136.59 Million |
|
MCH Group AG
SW:MCHN
|
$136.65 Million |
|
Thessaloniki Water Supply & Sewerage Co S.A
AT:EYAPS
|
$136.49 Million |
|
WiSoL CO.LTD
KQ:122990
|
$136.48 Million |
|
YFC-BonEagle Electric Co Ltd
TWO:6220
|
$136.36 Million |
|
Here Group Limited
NASDAQ:HERE
|
$136.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HLB Life Science Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 230,796,723,440 to 398,340,399,070, a change of 167,543,675,630 (72.6%).
- Net income of 6,137,881,570 contributed positively to equity growth.
- Share repurchases of 72,171,519,600 reduced equity.
- New share issuances of 72,171,519,590 increased equity.
- Other factors increased equity by 161,405,794,070.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩6.14 Billion | +1.54% |
| Share Repurchases | ₩72.17 Billion | -18.12% |
| Share Issuances | ₩72.17 Billion | +18.12% |
| Other Changes | ₩161.41 Billion | +40.52% |
| Total Change | ₩- | 72.59% |
Book Value vs Market Value Analysis
This analysis compares HLB Life Science Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.31x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.85x to 1.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩547.69 | ₩4300.00 | x |
| 2017-12-31 | ₩927.42 | ₩4300.00 | x |
| 2018-12-31 | ₩3017.82 | ₩4300.00 | x |
| 2019-12-31 | ₩3546.97 | ₩4300.00 | x |
| 2020-12-31 | ₩3050.54 | ₩4300.00 | x |
| 2021-12-31 | ₩2451.22 | ₩4300.00 | x |
| 2022-12-31 | ₩2307.67 | ₩4300.00 | x |
| 2023-12-31 | ₩2159.29 | ₩4300.00 | x |
| 2024-12-31 | ₩3270.06 | ₩4300.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HLB Life Science Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.00%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.35x
- Recent ROE (1.54%) is above the historical average (-10.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 10.44% | 3.84% | 1.09x | 2.48x | ₩58.95 Million |
| 2015 | -65.81% | -62.37% | 0.64x | 1.65x | ₩-19.63 Billion |
| 2016 | -4.52% | -2.96% | 0.51x | 2.99x | ₩-4.02 Billion |
| 2017 | 14.69% | 7.29% | 1.08x | 1.87x | ₩2.48 Billion |
| 2018 | -1.40% | -2.99% | 0.27x | 1.76x | ₩-24.97 Billion |
| 2019 | -2.28% | -6.67% | 0.28x | 1.21x | ₩-40.99 Billion |
| 2020 | -19.43% | -60.78% | 0.28x | 1.14x | ₩-84.51 Billion |
| 2021 | -19.97% | -91.88% | 0.20x | 1.10x | ₩-73.77 Billion |
| 2022 | -23.12% | -54.50% | 0.24x | 1.75x | ₩-77.75 Billion |
| 2023 | -2.59% | -6.11% | 0.23x | 1.83x | ₩-29.06 Billion |
| 2024 | 1.54% | 6.00% | 0.19x | 1.35x | ₩-33.70 Billion |
Industry Comparison
This section compares HLB Life Science Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $100,225,866,645
- Average return on equity (ROE) among peers: 0.62%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HLB Life Science Co. Ltd (067630) | ₩277.26 Billion | 10.44% | 0.62x | $136.50 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $298.46 Billion | -3.48% | 0.37x | $6.03 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $105.33 Billion | 1.93% | 1.32x | $33.52 Million |
| NatureCell Co.Ltd (007390) | $39.48 Billion | -1.17% | 0.30x | $688.81 Million |
| Sam-A Pharm. Co. Ltd (009300) | $110.58 Billion | 8.88% | 0.25x | $68.66 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $169.03 Billion | 11.15% | 0.19x | $89.89 Million |
| WooGene B&G Co. Ltd (018620) | $29.85 Billion | -6.92% | 1.60x | $13.13 Million |
| Oscotec Inc (039200) | $26.33 Billion | -13.85% | 0.55x | $990.30 Million |
| EstechPharma Co. Ltd (041910) | $111.39 Billion | 9.84% | 0.11x | $59.21 Million |
| Komipharm International Co. Ltd (041960) | $76.28 Billion | -3.69% | 0.60x | $380.81 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $35.53 Billion | 3.47% | 0.29x | $34.35 Million |
About HLB Life Science Co. Ltd
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendoc… Read more